Cover Image
市場調查報告書

飛鳥製藥的產品平台分析

ASKA Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 320914
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
飛鳥製藥的產品平台分析 ASKA Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014
出版日期: 2014年12月10日 內容資訊: 英文 30 Pages
簡介

飛鳥製藥是總公司設立於日本的製藥企業,從事醫藥品·動物用醫藥品·醫藥部外品·醫療用設備的製造開發及銷售,以及藥物資訊活動等。

本報告提供飛鳥製藥的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

飛鳥製藥的基本資料

  • 飛鳥製藥概要
  • 主要資訊
  • 企業資料

飛鳥製藥:R&D概要

  • 主要的治療範圍

飛鳥製藥:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

飛鳥製藥:開發中產品概況

  • 後期階段產品開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式

飛鳥製藥:藥物簡介

  • rifaximin
  • AKP-501
  • AKP-001

飛鳥製藥:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

飛鳥製藥:最新的開發平台資訊

飛鳥製藥:開發暫停中的計劃

飛鳥製藥:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

目錄
Product Code: GMDHC06612CDB

Summary

Global Markets Direct's, 'ASKA Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the ASKA Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ASKA Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of ASKA Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of ASKA Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the ASKA Pharmaceutical Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate ASKA Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of ASKA Pharmaceutical Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the ASKA Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of ASKA Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of ASKA Pharmaceutical Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of ASKA Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ASKA Pharmaceutical Co., Ltd. Snapshot
    • ASKA Pharmaceutical Co., Ltd. Overview
    • Key Information
    • Key Facts
  • ASKA Pharmaceutical Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • ASKA Pharmaceutical Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • ASKA Pharmaceutical Co., Ltd. - Pipeline Products Glance
    • ASKA Pharmaceutical Co., Ltd. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • ASKA Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
  • ASKA Pharmaceutical Co., Ltd. - Drug Profiles
    • rifaximin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AKP-501
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AKP-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • ASKA Pharmaceutical Co., Ltd. - Pipeline Analysis
    • ASKA Pharmaceutical Co., Ltd. - Pipeline Products by Target
    • ASKA Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
    • ASKA Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
    • ASKA Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
  • ASKA Pharmaceutical Co., Ltd. - Recent Pipeline Updates
  • ASKA Pharmaceutical Co., Ltd. - Dormant Projects
  • ASKA Pharmaceutical Co., Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ASKA Pharmaceutical Co., Ltd., Key Information
  • ASKA Pharmaceutical Co., Ltd., Key Facts
  • ASKA Pharmaceutical Co., Ltd. - Pipeline by Indication, 2014
  • ASKA Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014
  • ASKA Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014
  • ASKA Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2014
  • ASKA Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014
  • ASKA Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2014
  • ASKA Pharmaceutical Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2014
  • ASKA Pharmaceutical Co., Ltd. - Phase III, 2014
  • ASKA Pharmaceutical Co., Ltd. - Phase II, 2014
  • ASKA Pharmaceutical Co., Ltd. - Phase I, 2014
  • ASKA Pharmaceutical Co., Ltd. - Pipeline by Target, 2014
  • ASKA Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2014
  • ASKA Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2014
  • ASKA Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2014
  • ASKA Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2014
  • ASKA Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2014

List of Figures

  • ASKA Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2014
  • ASKA Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014
  • ASKA Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014
  • ASKA Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2014
  • ASKA Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2014
  • ASKA Pharmaceutical Co., Ltd. - Pipeline by Top 10 Route of Administration, 2014
  • ASKA Pharmaceutical Co., Ltd. - Pipeline by Top 10 Molecule Type, 2014
  • ASKA Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top